Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals, Inc. (SUPN) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company’s news flow reflects its role in neurology and psychiatry, with updates on commercial performance, pipeline progress, and strategic transactions.
Recent press releases highlight quarterly financial results, where Supernus reports net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products including MYOBLOC, XADAGO, and Osmolex ER. The company also reports collaboration revenue from ZURZUVAE, an oral treatment for postpartum depression, reflecting its collaboration with Biogen Inc. in the U.S. following Supernus’s acquisition of Sage Therapeutics, Inc.
Investors following SUPN news can expect coverage of product launches and commercialization updates, such as the U.S. launch and demand trends for ONAPGO, described as a subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson’s disease. Company announcements also discuss supply constraints and prioritization of existing patients when demand exceeds available inventory.
Supernus regularly issues news about its R&D pipeline, including clinical progress for SPN-817 in epilepsy, SPN-820 in depression, and SPN-443 for ADHD/CNS. In addition, the company announces participation in healthcare and therapeutics conferences hosted by investment banks and other organizations, providing forums where management discusses its CNS portfolio, financial performance, and strategy.
This news page aggregates these disclosures so readers can track earnings releases, collaboration developments around ZURZUVAE, clinical trial updates, and investor conference appearances related to Supernus Pharmaceuticals, Inc. (SUPN).
Supernus (Nasdaq: SUPN) reported record fourth-quarter total revenues of $211.6M (+21% YoY) and full-year 2025 revenues of $719.0M (+9% YoY). Combined growth-product revenues were $161.3M Q4 (+45% YoY) and $521.8M FY (+40% YoY).
The company completed the Sage acquisition, received FDA approval and launched ONAPGO (Q4 net sales $8.9M) and provided 2026 guidance of $840M–$870M total revenues with adjusted operating earnings of $140M–$170M. Cash and marketable securities were $308.7M at year-end.
Supernus Pharmaceuticals (Nasdaq: SUPN) said management will participate in three March 2026 investor conferences: TD Cowen (March 2), Jefferies Biotech on the Beach (March 10), and Barclays Global Healthcare (March 11).
Webcasts: TD Cowen and Barclays sessions will be webcast and archived for 60 days on the company website; investors should contact conference coordinators to arrange meetings.
Supernus Pharmaceuticals (Nasdaq: SUPN) will report fourth quarter and full year 2025 financial and business results after market close on February 24, 2026. Management will host a conference call and webcast the same day at 4:30 p.m. ET.
The event will include prepared remarks, a Q&A session, and a live webcast available on the company Investor Relations website; a replay will be accessible for 60 days following the call.
Lunai Bioworks (NASDAQ:LNAI) says its Augusta AI platform is now commercial after 12 months of development and is in active negotiations with pharmaceutical and drug‑discovery partners. The company highlights three revenue engines: AI drug discovery (CNS and new oncology pilot), AI biodefense programs targeting government contracts, and an allogeneic dendritic cell immunotherapy with published preclinical tumor regressions and an LOI for licensing.
The release emphasizes faster target validation via high‑throughput in vivo testing, near‑term pilots that can expand to commercial relationships, and ongoing efforts to finalize biodefense funding and a pharma royalty partnership.
Biogen (SUPN) announced that Health Canada issued a Notice of Compliance for ZURZUVAE (zuranolone) on December 9, 2025, for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth.
ZURZUVAE is a once-daily, 14-day oral single-course treatment with clinical benefits seen as early as Day 3, significant reduction by Day 15, and sustained effect through Day 45. Approval was supported by the NEST program (ROBIN and SKYLARK).
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that Jack A. Khattar, President and CEO, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025 at 3:20 p.m. ET.
Investors can request meetings through the Bank of America conference coordinator. A live audio webcast will be available via the company’s Events & Presentations page on www.supernus.com, and an archived replay will remain on the site for 60 days after the conference.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that Jack A. Khattar, President and CEO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:00 p.m. ET at the Lotte New York Palace in New York City.
Investors may request meetings via the Piper Sandler conference coordinator. A live audio webcast will be available via the company's Events & Presentations page at www.supernus.com, and an archived replay will be accessible on the company's website for 60 days after the conference.
Supernus (Nasdaq: SUPN) announced that Jack A. Khattar, President and CEO will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 9:30 a.m. EST (2:30 p.m. GMT).
Investors can request meetings through the Jefferies conference coordinator. A live audio webcast will be available via the company's Events & Presentations page at www.supernus.com, and an archived replay will be posted for 60 days after the conference.
Supernus (Nasdaq: SUPN) reported Q3 2025 total revenues of $192.1 million, a 9% increase versus Q3 2024, driven by combined growth-product sales of $149.2 million (+52%). The company completed the Sage acquisition on July 31, 2025, recording $20.2 million of collaboration revenue from ZURZUVAE for approximately two months post-close. Key product performance: Qelbree $81.4M (+31%), GOCOVRI $40.8M (+15%), and ONAPGO $6.8M in its first full commercial quarter. Cash and marketable securities were approximately $281.2M at September 30, 2025. The company raised full-year 2025 revenue guidance and updated operating and adjusted operating earnings guidance to reflect stronger results through nine months of 2025.
Supernus Pharmaceuticals (Nasdaq: SUPN) expects to report third quarter 2025 financial and business results after market close on Tuesday, November 4, 2025. Management will host a conference call and webcast the same day at 4:30 p.m. ET with Jack Khattar, President and CEO, and Tim Dec, SVP and CFO, presenting prepared remarks followed by a Q&A session.
A live webcast will be available in the Events & Presentations section of the investor relations site at www.supernus.com/investors. Participants may pre-register to receive a dial-in number and personalized conference code; dial-in is recommended 15 minutes before the start. A replay will be posted on the investor site and remain available for 60 days after the live call.